Achieve Life Sciences
ACHV
28 hedge funds and large institutions have $7M invested in Achieve Life Sciences in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 7 closing their positions.
183% more call options, than puts
Call options by funds: $195K | Put options by funds: $69K
0.81% more ownership
Funds ownership: 21.11% → 21.92% (+0.81%)
10% less funds holding
Funds holding: 31 → 28 (-3)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
30% less capital invested
Capital invested by funds: $9.97M → $7M (-$2.97M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$623K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$116K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$104K |
| 4 |
Jane Street
New York
|
+$76.7K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$72.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
-$266K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$115K |
| 3 |
OC
Oppenheimer & Co
New York
|
-$104K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$78.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62.1K |
ACHV Hedge Fund Activity: Q3 2022 in Review
28 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q3 2022, worth a combined $7M — down 30% from $9.97M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ACHV and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Long Focus Capital Management, adding an estimated $623K. The largest seller was Shay Capital, cutting an estimated $266K.
- 28 institutional investors held Achieve Life Sciences (ACHV) as of Q3 2022, down from 31 in Q2 2022.
- Funds reported $7M of Achieve Life Sciences stock for Q3 2022, down 30% quarter-over-quarter.
- 4 funds opened new Achieve Life Sciences positions in Q3 2022 and 7 closed out, a net change of -3 holders.
- The largest Achieve Life Sciences buyer in Q3 2022 was Long Focus Capital Management, an estimated $623K added.
- The largest Achieve Life Sciences seller in Q3 2022 was Shay Capital, an estimated $266K sold.
Based on aggregated 13F filings for Q3 2022.